Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05649059
Other study ID # 2206000688
Secondary ID
Status Not yet recruiting
Phase Phase 4
First received
Last updated
Start date December 2023
Est. completion date May 2025

Study information

Verified date September 2023
Source Massachusetts Institute of Technology
Contact Omar Rutledge, MS
Phone 617-324-2898
Email orutledge@mit.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to test whether a single-dose of Epidiolex (cannabidiol) is associated with reduced psychological, physiological, and neuroimaging measures of anxiety in people diagnosed with social anxiety disorder (SAD).


Description:

Using a randomized, double-blind, placebo-controlled, parallel-group study design, this scientific investigation will examine the effect of 3 milliliters (mL) of Epidiolex (100mg cannabidiol/mL) on behavioral, physiological, and neuroimaging measures of anxiety in subjects diagnosed with SAD. The study will enroll 50 subjects with SAD who will be randomized in a double-blind manner to receive either Epidiolex or placebo before experiencing the Trier Social Stress Test (TSST), the gold-standard for ethically inducing stress in a controlled laboratory setting. Following the TSST, neuroimaging measures of emotional processing and self-referential processing will be acquired using functional magnetic resonance imaging (fMRI). This study will be conducted primarily at Massachusetts Institute of Technology with research and clinical support from Massachusetts General Hospital.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 50
Est. completion date May 2025
Est. primary completion date December 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria: - Ability and willingness to provide written informed consent. - Sufficiently fluent in English to participate in the trial. - Between 18-55 years of age (inclusive). - Right-hand dominant. - Current medications are stable for past 30 days (no changes to dose or frequency). - Negative result on pregnancy test (if female). - Negative result on urine drug screening. - Current diagnosis of social anxiety disorder (QuickSCID-5). - Liebowitz Social Anxiety Scale (LSAS = 60). Exclusion Criteria: - History of bipolar disorder, schizophrenia, psychosis, delusional disorders. - History of eating disorder within past 6 months. - History of any traumatic brain injury. - Currently diagnosed with diabetes mellitus. - Presence of severe medical illness that would prevent completion of study procedures. - Presence of significant neurological illness or cognitive dysfunction (e.g.; seizures, dementia). - History of substance use disorder within past 6 months (other than nicotine and caffeine). - Use of any cannabis-containing products in past 30 days (CBD or THC). - Use of beta-blockers or benzodiazepines in past 2 weeks. - History of claustrophobia. - Contraindications for MRI (e.g.; shrapnel). - Presence of any other medical condition that, in the investigator's opinion, may interfere with the study procedures. - Use of concomitant medication that has a strong interaction with CYP3A4 or CYP2C19 (as assessed through Lexicomp). - History of liver disease. - History of hypersensitivity to cannabinoids. - History of hypersensitivity to sesame seed oil. - Currently breastfeeding (if female).

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Cannabidiol
Participants randomized to the cannabidiol arm will receive 3mL of Epidiolex (100mg cannabidiol/mL) in a single-dose.
Placebo
Participants randomized to the placebo arm will receive 3mL of placebo (sesame seed oil) in a single dose.

Locations

Country Name City State
United States Massachusetts General Hospital Boston Massachusetts
United States Massachusetts Institute of Technology Cambridge Massachusetts

Sponsors (2)

Lead Sponsor Collaborator
Massachusetts Institute of Technology Massachusetts General Hospital

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Differences in fMRI BOLD Response Patterns of brain activation measured as blood-oxygenation-level dependent (BOLD) signals will be assessed using 3.0 Tesla (3T) functional magnetic resonance imaging (fMRI). Several exploratory imaging paradigms, including the emotional face-matching task (EFMT) and the self-referential comment task (SRCT), will be used to examine differences between participants who receive Epidiolex (cannabidiol) and those that receive placebo. Neuroimaging will begin approximately 210 minutes after drug administration (+45 minutes after the TSST). +45 minutes
Primary Change in Acute Subjective Anxiety Subjective anxiety will be assessed with a modified Visual Analog Mood Scale (VAMS) which utilizes a vertical 100 millimeter (mm) bipolar visual scale between two opposing moods consisting of the following word pairs: calm-excited, relaxed-tense, and tranquil-troubled. Total subjective anxiety for each timepoint will be the average distance from the bottom for the three-question battery. VAMS will be assessed 15 minutes before drug administration (-180 minutes before start of TSST), 150 minutes after drug administration (-15 minutes before start of TSST), after the Anticipation Phase (-5 minutes before start of TSST), after the Stress Procedures (+10 minutes after start of TSST), after 5 minutes in the Recovery Phase (+20 minutes after start of TSST), and 15 minutes after start of the Recovery Phase (+30 minutes after start of TSST). -180 minutes, -15 minutes, -5 minutes, +10 minutes, +20 minutes, +30 minutes
Secondary Differences in Salivary Alpha Amylase Physiological stress will be assessed indirectly with salivary alpha amylase (sAA) activity which is regulated by the sympathetic branch of the autonomic nervous system. Samples will be collected using the SalivaBio Oral Swab (SOS) from Salimetrics. Participants will place the SOS in their mouth for 1-2 minutes at each timepoint to collect saliva. sAA will be assessed 15 minutes before drug administration (-180 minutes before start of TSST), 150 minutes after drug administration (-15 minutes before start of TSST), after the Anticipation Phase (-5 minutes before start of TSST), after the Stress Procedures (+10 minutes after start of TSST), after 5 minutes in the Recovery Phase (+20 minutes after start of TSST), and 15 minutes after start of the Recovery Phase (+30 minutes after start of TSST). -180 minutes, -15 minutes, -5 minutes, +10 minutes, +20 minutes, +30 minutes
See also
  Status Clinical Trial Phase
Completed NCT02590770 - Gaze Contingent Feedback in Social Anxiety Disorder N/A
Completed NCT00751465 - Dysfunctional Attention Processes in Fear of Blushing: Specificity and Changeability N/A
Completed NCT03630783 - Combined CBM For Social Anxiety in Turkey N/A
Terminated NCT00182533 - Sertraline in Generalized Social Phobia With Co-Occurring Anxiety and Mood Disorders Phase 4
Completed NCT01470469 - SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP) Phase 2
Completed NCT01557894 - Internet Treatment for Social Phobia in Romania N/A